| Trial ID: | L0328 |
| Source ID: | NCT04607655
|
| Associated Drug: |
GB1211
|
| Title: |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
|
| Acronym: |
--
|
| Status: |
Withdrawn
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-alcoholic Steatohepatitis (NASH)
|
| Interventions: |
Drug: GB1211|Drug: Placebo
|
| Outcome Measures: |
Safety and Tolerability of GB1211|Pharmacokinetics of GB1211
|
| Sponsor/Collaborators: |
Galecto Biotech AB|Covance
|
| Gender: |
All
|
| Age: |
18 Years to 75 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 1/Phase 2
|
| Enrollment: |
0
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
March 2021
|
| Completion Date: |
July 2022
|
| Results First Posted: |
--
|
| Last Update Posted: |
February 4, 2021
|
| Locations: |
--
|
| URL: |
https://ClinicalTrials.gov/show/NCT04607655
|
